ZANTAC 150
LOE ApproachingNDAORALTABLET
Approved
Jun 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 150 is an oral tablet small-molecule H2-receptor antagonist approved in 1983 for acid-related gastrointestinal disorders. The drug reduces gastric acid secretion and is indicated for conditions such as peptic ulcer disease and gastroesophageal reflux disease (GERD). It represents a mature, well-established therapeutic class with decades of clinical use.
LOE Approaching
LOE approaching signals potential reduction in brand team headcount; commercial roles should expect consolidation or transition to generic/OTC support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
Working on ZANTAC 150 offers limited career growth due to LOE proximity and mature market saturation; most positions focus on defensive brand management and generic conversion support. Career progression may require lateral moves to growth-stage GSK products or competitor acquisitions.
Brand Manager
Worked on ZANTAC 150 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.